1. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921. doi: 10.1158/1078-0432.ccr-06-2610
2. Zhu A Liu W, Gotlieb V, et al. (2015) The rapidly evolving therapies for advanced melanoma-towards immunotherapy. Molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. pii: S1040-8428(15)30091-3. doi:016/j.critrevonc.2015.12.002
3. Garon EB (2015) Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 42(Suppl 2):S11-8. doi: 10.1053/j.seminoncol.2015.09.019 Epub 2015 Sep 11
4. Ataka S, Nishio M, Hida T, et al (2015) Phase II study of anti-PD-1 antibody nivolumab for Japanese patients with non small cell lung cancer. The 56th annual meeting of lung cancer (abstract) http://www.haigan.gr.jp/journal/am/2015a/15a_ws040WS4-1.html
5. Herbst RS, LoRusso PM, Purdom M et al (2003) Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 4:366–369